Effectiveness of bemitil in recurrent erysipelas

Ratnikova, L.I.

Klinicheskaia Meditsina 69(7): 89-90

1991


ISSN/ISBN: 0023-2149
PMID: 1942990
Document Number: 4048
The trial entered 66 patients with recurrent erysipelas treated conventionally with addition of either immunostimulator bemitil (0.25-0.5 g/day orally for 5-7 days) or placebo. The bemitil group was free of intoxication symptoms and local manifestations, discharged from hospital sooner than the controls. Therapeutic efficacy of bemitil is due to its promotion of mononuclear phagocytes function which acts as an essential mechanism of antibacterial defence activation in patients with recurrent erysipelas.

Document emailed within 1 workday
Secure & encrypted payments

Effectiveness of bemitil in recurrent erysipelas